Vietnam’s Pharmaceutical Contract Manufacturing Market Builds Momentum as Local Production Moves Up the Value Chain

Vietnam is emerging as an increasingly attractive pharmaceutical manufacturing location as the country expands domestic production, upgrades manufacturing standards and seeks to capture more value from its rapidly growing medicines market.

Pharmaceutical contract manufacturing — spanning active pharmaceutical ingredients (APIs), finished dosage forms, biologics, sterile manufacturing, fill-finish and packaging — is positioned to benefit from this transition.

While no reliable publicly disclosed standalone value is currently available for Vietnam's pharmaceutical contract manufacturing market, dedicated country-level market research confirms that the sector is established and expanding. A reasonable working estimate places the market at approximately US$350–500 million in 2025, with the potential to reach around US$600–850 million by 2030.

These figures are derived estimates rather than published country-level market values. However, the direction of growth is supported by both Vietnam's expanding pharmaceutical industry and rapid growth in pharmaceutical outsourcing across Asia-Pacific.

A US$16 billion pharmaceutical market in sight

The wider market provides a powerful foundation for manufacturing investment.

Vietnam's pharmaceutical market is estimated at US$8.58 billion in 2025 and is forecast to reach US$16.03 billion by 2032, representing annual growth of 9.33%.

As demand increases, Vietnam is looking to capture a greater proportion of the pharmaceutical value chain domestically rather than relying predominantly on imported products and ingredients.

The country's pharmaceutical development strategy targets domestically manufactured medicines accounting for approximately 80% of medicines used and 70% of total market value by 2030.

Vietnam has an even broader ambition: to become a regional centre for high-value pharmaceutical manufacturing.

That includes attracting technology transfer and contract manufacturing involving originator medicines, vaccines, biological products and biosimilars — creating opportunities extending well beyond conventional generic drug production.

Asia-Pacific contract manufacturing is accelerating

The regional outsourcing market is expanding rapidly.

Asia-Pacific's pharmaceutical contract manufacturing market generated approximately US$37.7 billion in 2025 and is forecast to reach US$88.6 billion by 2033, growing at approximately 11.4% annually.

API manufacturing currently represents the largest segment of the regional market, while pharmaceutical packaging is forecast to be among the fastest-growing service categories.

Biopharmaceutical outsourcing represents another major growth area. Asia-Pacific's biopharmaceutical contract manufacturing market alone was valued at approximately US$13.1 billion in 2025 and is forecast to reach almost US$30.9 billion by 2033.

For Vietnam, this regional expansion creates an opportunity to establish itself as an additional manufacturing location within an increasingly diversified Asian pharmaceutical supply chain.

Moving from volume to value

The most important development in Vietnam is not simply increasing manufacturing capacity. It is the progressive improvement in the quality and sophistication of that capacity.

Domestic manufacturers are investing in WHO-GMP, EU-GMP and other internationally recognised manufacturing standards, creating facilities capable of producing higher-value pharmaceutical products and competing for more sophisticated manufacturing contracts.

This is already visible among Vietnamese manufacturers.

Companies such as Imexpharm have invested significantly in EU-GMP manufacturing infrastructure. Imexpharm operates multiple EU-GMP-certified manufacturing facilities and has previously manufactured products under franchise or production arrangements for international pharmaceutical companies.

This evolution creates the foundations for Vietnam to move from primarily manufacturing conventional generics towards more advanced production involving complex formulations, sterile products, injectables, biologics and specialist pharmaceuticals.

APIs remain a major opportunity

Active pharmaceutical ingredients represent another strategic opportunity.

Vietnam's pharmaceutical industry remains dependent on imported pharmaceutical ingredients, making greater API localisation an important part of the country's longer-term pharmaceutical manufacturing strategy.

The government's 2030 pharmaceutical strategy targets domestic production of approximately 20% of the raw-material requirements of domestic pharmaceutical manufacturing.

For API manufacturers, chemical suppliers, processing technology companies and pharmaceutical engineering businesses, this represents a potentially significant opportunity.

It also increases demand for the supporting manufacturing ecosystem — including reactors, filtration, separation, drying, milling, containment, process analytical technology, quality control and environmental management systems.

Biologics and fill-finish open a higher-value opportunity

One of the most commercially interesting areas is likely to be biopharmaceutical manufacturing.

Vietnam's strategy explicitly includes vaccines, biological medicines and biosimilars as areas in which the country wants to strengthen domestic capabilities and technology transfer.

These products require substantially more sophisticated manufacturing infrastructure than conventional oral solid-dose medicines.

Growth in biologics therefore creates demand for single-use bioprocessing systems, bioreactors, chromatography, filtration, sterile processing, cleanrooms, cold-chain infrastructure, aseptic fill-finish, quality assurance and analytical technologies.

A dedicated Vietnam fill-finish pharmaceutical contract manufacturing market is already being tracked by market researchers, covering both small and large molecules and sterile and non-sterile production.

For international technology and manufacturing partners, this represents an opportunity to participate not only as outsourced manufacturers, but also as suppliers of the technologies that allow Vietnamese pharmaceutical companies to increase production sophistication.

International pharmaceutical companies have another route into Vietnam

Contract manufacturing can also provide international pharmaceutical companies with an alternative route into the Vietnamese market.

Rather than immediately developing wholly owned manufacturing infrastructure, international companies can work with qualified domestic manufacturers to establish local production, transfer technology or manufacture products under licence.

As Vietnam strengthens manufacturing standards, the pool of potential partners capable of meeting international requirements should increase.

This creates opportunities for CMOs and CDMOs, pharmaceutical manufacturers, formulation specialists, technology-transfer partners, engineering companies, equipment suppliers and quality and regulatory consultants.

A growing ecosystem around pharmaceutical manufacturing

The opportunity extends well beyond companies physically producing medicines.

A larger and more sophisticated manufacturing sector requires an extensive supporting supply chain.

That includes suppliers of pharmaceutical processing equipment, cleanrooms, HVAC, water systems, laboratory equipment, analytical instrumentation, process automation, serialization and track-and-trace systems, inspection machines, primary and secondary packaging, cold-chain technology and warehouse automation.

Quality control and regulatory compliance will become increasingly important as manufacturers move towards EU-GMP, PIC/S-GMP and other international standards.

Companies providing LIMS, environmental monitoring, PAT, validation, regulatory consulting, contamination control and quality-management technology therefore form part of the same commercial opportunity.

Vietnam's pharmaceutical manufacturing opportunity is changing

Vietnam should not yet be positioned alongside China or India as a global pharmaceutical outsourcing powerhouse. Its contract manufacturing sector is considerably smaller and its capabilities continue to develop.

But that is also part of the opportunity.

The combination of a pharmaceutical market heading towards US$16 billion, government support for domestic manufacturing, higher GMP standards, technology-transfer ambitions and rapid growth in Asian pharmaceutical outsourcing creates favourable conditions for continued investment.

Vietnam's next stage of pharmaceutical development is likely to be defined less by simply producing more medicines and increasingly by producing higher-value medicines to higher international standards.

For pharmaceutical manufacturers, CMOs, CDMOs and companies supplying the technology behind modern pharmaceutical production, Vietnam is becoming an increasingly important market to watch.

READ THE FULL INSIGHTS REPORT